An Open-Label, Randomized, Multicenter Study of the Safety, Tolerability, and Immunogenicity of Gardasil (V501) Given Concomitantly With Menactra(TM) and ADACEL(TM) in Healthy Adolescents 11-17 Years of Age.

Trial Profile

An Open-Label, Randomized, Multicenter Study of the Safety, Tolerability, and Immunogenicity of Gardasil (V501) Given Concomitantly With Menactra(TM) and ADACEL(TM) in Healthy Adolescents 11-17 Years of Age.

Completed
Phase of Trial: Phase III

Latest Information Update: 11 Jun 2014

At a glance

  • Drugs Human papillomavirus vaccine recombinant quadrivalent Merck (Primary) ; DTaP vaccine; Meningococcal vaccine groups A C Y W-135 conjugate
  • Indications Cervical cancer; Cervical intraepithelial neoplasia; Diphtheria; Genital warts; Human papillomavirus infections; Meningococcal group A infections; Meningococcal group C infections; Meningococcal group W-135 infections; Meningococcal group Y infections; Meningococcal infections; Pertussis; Tetanus
  • Focus Pharmacodynamics
  • Sponsors Merck & Co
  • Most Recent Events

    • 03 May 2010 Results have been published in full in the journal Pediatrics.
    • 05 May 2009 Results presented at 2009 Annual Meeting of the Pediatric Academic Societies
    • 03 Aug 2008 Additional trial identifier V501-025 reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top